New Trial Aims to Optimize Methotrexate Therapy in Rheumatoid Arthritis

Key Takeaways

• MethMax has begun as a randomized, assessor-blinded European trial in patients with active rheumatoid arthritis.
• The protocol compares optimized oral methotrexate dosing with subcutaneous methotrexate at the same 25 mg weekly target dose, with remission at 24 weeks as the main outcome.
• All participants receive short-term glucocorticoid bridging, and the study protocol has been published in Trials.

The MethMax trial has launched as an international, multicenter, prospective, randomized, assessor-blinded study examining whether methotrexate dosing and route can be optimized in active rheumatoid arthritis. The protocol sets out a practical comparison built around a 25 mg weekly methotrexate target dose rather than a new agent. Investigators are examining whether these adjustments can improve remission by making routine use more systematic across participating European centers. The study focuses on refining an established therapy rather than introducing a different drug.

Methotrexate is described as a widely recommended first-line treatment in rheumatoid arthritis because of established efficacy, safety, and affordability. Karolina Anderle and Helga Lechner-Radner, at the Division of Rheumatology, Department of Medicine III, Medical University of Vienna, are leading the study. Researchers note that routine use may be constrained by insufficient dose escalation or delayed switching to subcutaneous administration. MethMax is part of the SQUEEZE consortium, supported through the European Union’s Horizon Europe program, and centers on improving how an existing therapy is used. The study is framed around improving outcomes before moving to more complex treatment approaches in active disease. The focus remains on whether practical optimization can raise remission without changing the underlying drug.

The trial plans to enroll 182 patients with active rheumatoid arthritis across centers in seven European countries. Over 24 weeks, all participants receive weekly methotrexate targeted to 25 mg together with a short-term glucocorticoid bridging regimen. Regular follow-up assessments are scheduled throughout the study within a standardized treatment approach for all participants. This setup gives both groups the same weekly target dose and the same bridging background treatment. The central comparison is optimized oral escalation versus subcutaneous delivery at an equivalent methotrexate target dose.

The primary objective is to determine whether these methotrexate strategies increase the proportion of patients who reach remission after 24 weeks. The protocol also includes systematic evaluation of clinical outcomes, safety, and patient-reported measures throughout follow-up. Exploratory work will examine biomarkers, methotrexate polyglutamates in blood, and metabolites obtained from finger sweat. Investigators also intend to assess adherence through digital tools and patient-reported measures alongside these biologic readouts over time. No efficacy or adverse-event results are available because enrollment and follow-up are part of the planned study period rather than a completed analysis.

Reported from Vienna on April 21, 2026, the trial launch emphasizes how best to use methotrexate already established in routine care. The protocol has been published in Trials, making the study design and planned assessments publicly available. The design tests common methotrexate decisions under controlled trial conditions. The publication aligns the launch with a comparative strategy study focused on dose escalation and route optimization in active rheumatoid arthritis.